Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Darifenacin Hydrobromide
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Laboratorio Elea Phoenix
Deal Size : Inapplicable
Deal Type : Inapplicable
Single Dose Bioequivalence Study of Darifenacin Tablets 7.5 mg in Fed Healthy Volunteers.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 27, 2010
Lead Product(s) : Darifenacin Hydrobromide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Laboratorio Elea Phoenix
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darifenacin Hydrobromide
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Laboratorio Elea Phoenix
Deal Size : Inapplicable
Deal Type : Inapplicable
Single Dose Two-periods Crossover Bioequivalence Study of Darifenacin Tablets in Healthy Volunteers.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 25, 2010
Lead Product(s) : Darifenacin Hydrobromide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Laboratorio Elea Phoenix
Deal Size : Inapplicable
Deal Type : Inapplicable